A new study published by the journal Neurochemical Research, and published online by the U.S. National Institute of Health, has confirmed past research that shows cannabidiol to be an anti-seizure agent.
For the study; “The National Institute of Neurological Disorders and Stroke (NINDS) funded Epilepsy Therapy Screening Program (ETSP) investigated CBD in a battery of seizure models using a refocused screening protocol aimed at identifying pharmacotherapies to address the unmet need in pharmacoresistant epilepsy”.
Applying this new screening workflow, CBD was investigated in multiple mouse and rat models of acute seizures. Following intraperitoneal (i.p.) pretreatment, “CBD produced dose-dependent protection in the acute seizure models.” In chronic models, “CBD produced dose-dependent protection in the corneal kindled mouse”.